Oncolytics Biotech Inc. (ONCY) Earnings History
Annual and quarterly earnings data from 1999 to 2024
Loading earnings history...
ONCY EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ONCY Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export ONCY earnings history in CSV or JSON format
Free sign-in required to download data
Oncolytics Biotech Inc. (ONCY) Earnings Overview
As of May 8, 2026, Oncolytics Biotech Inc. (ONCY) reported trailing twelve-month net income of -$35M, reflecting +0.0% year-over-year growth. The company earned $-0.35 per diluted share over the past four quarters.
Looking at the long-term picture, ONCY's historical earnings data spans multiple years. The company achieved its highest annual net income of -$574,462 in fiscal 1999.
Oncolytics Biotech Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), CLDX (-$259M net income, -17253.3% margin), NKTR (-$164M net income, -297.1% margin), ONCY has comparable earnings metrics. Compare ONCY vs IMVT →
ONCY Earnings vs Peers
Earnings metrics vs comparable public companies
ONCY Historical Earnings Data (1999–2024)
26 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$32M | -54.2% | -$35M | $-0.41 | - | - |
| 2023 | -$21M | -7.8% | -$25M | $-0.41 | - | - |
| 2022 | -$19M | +9.1% | -$21M | $-0.43 | - | - |
| 2021 | -$21M | -25.0% | -$21M | $-0.49 | - | - |
| 2020 | -$17M | +63.2% | -$19M | $-0.48 | - | - |
| 2019 | -$46M | -167.4% | -$21M | $-2.06 | - | - |
| 2018 | -$17M | -9.1% | -$17M | $-1.06 | - | - |
| 2017 | -$16M | -3.1% | -$16M | $-1.12 | - | - |
| 2016 | -$15M | -10.3% | -$15M | $-1.20 | - | - |
| 2015 | -$14M | +26.3% | -$14M | $-1.16 | - | - |
See ONCY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ONCY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ONCY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonONCY — Frequently Asked Questions
Quick answers to the most common questions about buying ONCY stock.
Is ONCY growing earnings?
ONCY TTM EPS: $-0.35. Net income: $-35M. Earnings growth: +0.0%.
What are ONCY's profit margins?
Oncolytics Biotech Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ONCY's earnings?
ONCY earnings data spans 1999-2024. The current earnings trend is +0.0% YoY. Historical data enables comparison across business cycles.